As of Jul 21
| -0.61 / -1.51%|
The 5 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 42.00, with a high estimate of 50.00 and a low estimate of 38.00. The median estimate represents a +5.55% increase from the last price of 39.79.
The current consensus among 9 polled investment analysts is to Hold stock in Haemonetics Corp. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.